Инфекция Helicobacter pylori и гематологические заболевания
https://doi.org/10.31146/1682-8658-ecg-198-2-103-110
Аннотация
Инфекция Helicobacter pylori выявляется более чем у половины популяции и может быть ассоциирована с гематологическими заболеваниями. В обзоре представлен анализ литературы о связи инфекции Helicobacter pylori с MALT-лимфомой, железодефицитной анемией, В12-дефицитной анемией, идиопатической тромбоцитопенической пурпурой и другой гематологической патологией.
Об авторах
А. Н. Богданов
Федеральное государственное бюджетное образовательное учреждение высшего образования Санкт-Петербургский государственный университет
Россия
Россия
С. В. Волошин
ФГБУ «Российский НИИ гематологии и трансфузиологии ФМБА России»
Россия
Россия
Т. Г. Кулибаба
Федеральное государственное бюджетное образовательное учреждение высшего образования Санкт-Петербургский государственный университет
Россия
Россия
Список литературы
1. Diaconu S., Predescu A., Moldoveanu A., et al. Helicobacter pylori infection: old and new. J Med Life. 2017 Apr-Jun; 10(2): 112-117.
2. Robinson K., Atherton J. C. The spectrum of Helicobacter-mediated diseases. Annu Rev Pathol. 2021; 16:123-144. doi: 10.1146/annurev-pathol-032520-024949
3. Tsay F-W., Hsu P-I. H. pylori infection and extra-gastroduodenal diseases. J Biomed Sci. 2018; 25: 65. doi: 10.1186/s12929-018-0469-6
4. Gravina A. G., Zagari R. M., De Musis C., et al. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol. 2018 Aug 7; 24(29): 3204-3221. doi: 0.3748/wjg.v24.i29.3204
5. Santos M. L.C., de Brito B. B., da Silva F. A., et al. Helicobacter pylori infection: beyond gastric manifestations. World J Gastroenterol. 2020 Jul 28; 26(28): 4076-4093. doi: 10.3748/wjg.v26.i28.4076
6. Campuzano-Maya G. Helicobacter pylori and hematologic diseases, extradigestive manifestations of Helicobacter pylori infection - an overview. Bruna Maria Roesler, IntechOpen. doi: 10.5772/62971
7. Jee S. R. Helicobacter pylori and hematologic diseases. Korean J Helicobacter Up Gastrointest Res. 2020;20(1):11-20. doi: 10.7704/kjhugr.2019.047
8. Müller A.M.S., Ihorst G., Mertelsmann R., Engelhardt M. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol. 2005 Jan;84(1):1-12.
9. Filip P. V., Curiureanu D., Diaconu L. S., et al. MALT lymphoma: epidemiology, clinical diagnosis and treatment. J Med Life. 2018 Jul-Sep; 11(3): 187-193. doi: 10.25122/jml-2018-0035
10. Ptushkin V. V., Poddubnaya I. V., Osmanov E. A., et al. Marginal zone lymphoma. Clinical guidelines. Moscow. 2020. 55 P. (in Russ.)@@ Птушкин В. В., Поддубная И. В., Османов Е. А. и др. Лимфома маргинальной зоны. Клинические рекомендации. М.2020. - 55 с.
11. Chaparro C. M., Suchdev P. S. Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. Ann N Y Acad Sci. 2019; 1450(1): 15-31.
12. Blecker U., Renders F., Lanciers S., et al. Syncopes leading to the diagnosis of a helicobacter pylori positive chronic active haemorrhagic gastritis. Eur J Pediatr. 1991;150(8):560-561.
13. Pounder R.E., Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther. 1995; 9 Suppl 2: 33-39.
14. Qu X.H., Huang X. L., Xiong P., et al. Does helicobacter pylori infection play a role in iron deficiency anemia? A meta-analysis. World J Gastroenterol. 2010;16(7):886-896.
15. Yuan W., Li Y., Yang K., et al. Iron deficiency anemia in helicobacter pylori infection: meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2010;45(6):665-676.
16. Mayev I. V., Kochetov S. A. Clinical significance of Helicobacter pylori infection in iron-deficiency anemia: features of comprehensive treatment approach.Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(1):29-36. (In Russ.) doi: 10.22416/1382-4376-2016-26-1-29-36@@ Маев И. В., Кочетов С. А. Клиническое значение инфекции Helicobacter pylori у пациентов с железодефицитной анемией: особенности комплексного подхода к терапии. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016;26(1):29-36. doi: 10.22416/1382-4376-2016-26-1-29-36
17. Hershko C., Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood. 2014;123:326-333.
18. Tan H.J., Goh K. L. Extragastrointestinal manifestations of Helicobacter pylori infection: facts or myth? A critical review. J Dig Dis. 2012;13:342-349.
19. Boyanova L. Role of helicobacter pylori virulence factors for iron acquisition from gastric epithelial cells of the host and impact on bacterial colonization. Future Microbiol. 2011;6(8):843-846.
20. Capurso G., Lahner E., Marcheggiano A., et al. Involvement of the corporal mucosa and related changes in gastric acid secretion characterize patients with iron deficiency anaemia associated with helicobacter pylori infection. Aliment Pharmacol Ther. 2001;15:1753-1761.
21. Pagani A., Nai A., Silvestri L., Camaschella C. Hepcidin and anemia: a tight relationship. Front Physiol. 2019; 10: 1294. doi: 10.3389/fphys.2019.01294
22. Joosten E. Iron deficiency anemia in older adults: a review. Geriatr Gerontol Int. 2018;18: 373-379. doi.org/10.1111/ggi.13194
23. Sato Y., Yoneyama O., Azumaya M., et al. The relationship between iron deficiency in patients with Helicobacter pylori-infected nodular gastritis and the serum prohepcidin level. Helicobacter. 2015; 20: 11-18. doi: 10.1111/hel.12170
24. Ozkasap S., Yarali N., Isik P., et al. The role of prohepcidin in anemia due to Helicobacter pylori infection. Pediatr Hematol Oncol. 2013;30:425-431.
25. Azab S.F., Esh A. M. Serum hepcidin levels in Helicobacter pylori-infected children with iron-deficiency anemia: a case-control study. Ann Hematol. 2013; 92: 1477-1483. doi: 10.1007/s00277-013-1813-2
26. Malfertheiner P., Megraud F., O’Morain C.A., et al. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut. 2012 May;61(5):646-64. doi: 10.1136/gutjnl-2012-302084
27. Malfertheiner P., Megraud F., O’Morain C.A., et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan;66(1):6-30. doi: 10.1136/gutjnl-2016-312288
28. Tseng D. S., Li D., Cholleti S. M., et al. Effect of Helicobacter pylori treatment on unexplained iron deficiency anemia. Perm J. 2019;23: 18-195. doi: 10.7812/TPP/18-195
29. John J., Baltodano J. D., Mehta N., et al. Unexplained iron deficiency anemia: does Helicobacter pylori have a role to play? Gastroenterol Rep (Oxf). 2018 Aug; 6(3): 215-220. doi: 10.1093/gastro/goy001
30. Hou B., Zhang M., Liu M., et al. Association of active Helicobacter pylori infection and anemia in elderly males. BMC Infectious Diseases. 2019. 19(1). doi:10.1186/s12879-019-3849-y
31. Rockey D.C., Altayar O., Falck-Ytter Y., Kalmaz D. AGA Technical review on gastrointestinal evaluation of iron deficiency anemia. Gastroenterology. 2020;159 (3):1097-1119.
32. Lukina E.A., Tsvetaeva N. V., Dvirnyk V. N. Iron deficiency anemia. Clinical guidelines. Moscow. 2020. 34 p. (in Russ.)@@ Лукина Е. А., Цветаева Н. В., Двирнык В. Н. Железодефицитные анемии. Клинические рекомендации. М., 2020. - 34 с
33. O’Connor H.J., Axon A. T., Dixon M. F. Campylobacter-like organisms unusual in type a (pernicious anaemia) gastritis. Lancet. 1984;2(8411):1091.
34. Warren J.R., Marshall B. Unidentified curved baccilli on gastric epithelium in active chronic gastritis. Lancet. 1983; 1:1273-1275.
35. Fong T.L., Dooley C. P., Dehesa M., et al. Helicobacter pylori infection in pernicious anemia: a prospective controlled study. Gastroenterology. 1991; 100: 328-332.
36. Valle J., Kekki M., Sipponen P., Ihamaki T., Siurala M. Long-term course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol. 1996; 31: 546-550.
37. Lahner E., Persechino S., Annibale B. Micronutrients (other than iron) and Helicobacter pylori infection: a systematic review. Helicobacter. 2012; 17: 1-15. doi: 10.1111/j. 1523-5378.2011.00892.x
38. Marino M.C., de Oliveira C. A., Rocha A. M., et al. Long-term effect of Helicobacter pylori eradication on plasma homocysteine in elderly patients with cobalamin deficiency. Gut. 2007; 56: 469-474.
39. Lukina E. A., Tsvetaeva N. V., Dvirnyk V. N. В12 deficiency anemia. Clinical guidelines. Moscow. 2020. 28 p. (in Russ.)@@ Лукина Е. А., Цветаева Н. В., Двирнык В. Н. В12-дефицитная анемия. Клинические рекомендации. М., 2020. - 28 с.
40. Rodeghiero F., Stasi R., Gernsheimer T., et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009; 113: 2386-2393. doi: 10.1182/blood-2008-07-162503
41. Gasbarrini A., Franceschi F., Tartaglione R., et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet. 1998;12:878. doi: 10.1016/S0140-6736 (05) 60004-9
42. Tohda S., Ohkusa T. Resolution of refractory idiopathic thrombocytopenic purpura after eradication of Helicobacter pylori. Am J Hematol. 2000; 65: 329-330.
43. Grimaz S., Damiani D., Brosolo P., et al. Resolution of thrombocytopenia after treatment for Helicobacter pylori: a case report. Haematologica. 1999; 84: 283-284.
44. Kurekci A.E., Atay A. A., Sarici S. U., Ozcan O.Complete platelet recovery after treatment of Helicobacter pylori infection in a child with chronic immune thrombocytopenic purpura: a case report. Pediatr Hematol Oncol. 2004; 21: 593-596.
45. Campuzano-Maya G. Hematologic manifestations of Helicobacter pylori infection. World J Gastroenterol. 2014; 20: 12818-12838. doi: 10.3748/wjg.v20.i36.12818
46. Jarque I., Andreu R., Lopis I. Absence of platelet response after eradication of Helicobacter pylori infection in patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2001; 115: 1002-1003.
47. Michel M., Khellaf M., Desforges L., et al. Autoimmune thrombocytopenic purpura and Helicobacter pylori infection. Arch Intern Med. 2002; 162: 1033-1036.
48. Ahn E.R., Tiede M. P., Jy W., et al. Platelet activation in Helicobacter pylori-associated idiopathic thrombocytopenic purpura: eradication reduces platelet activation but seldom improves platelet counts. Acta Haematol. 2006; 116: 19-24.
49. Satoh T., Pandey J. P., Okazaki Y., et al. Single nucleotide polymorphism of interleukin-1beta associated with Helicobacter pylori infection in immune thrombocytopenic purpura. Tissue Antigens. 2009;73:353-357.
50. Asahi A., Nishimoto T., Okazaki Y., et al. Helicobacter pylori eradication shifts monocyte Fc gamma receptor balance toward inhibitory Fc gamma RIIB in immune thrombocytopenic purpura patients. J Clin Invest. 2008;118:2939-2949.
51. Kodama M., Kitadai Y., Ito M., et al. Immune response to CagA protein is associated with improved platelet count after Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura. Helicobacter. 2007;12:36-42.
52. Bai Y., Wang Z., Bai X., et al. Cross-reaction of antibody against Helicobacter pylori urease B with platelet glycoprotein IIIa and its significance in the pathogenesis of immune thrombocytopenic purpura.Int J Hematol. 2009; 89: 142-149. doi: 10.1007/s12185-008-0247-4. 68
53. Franchini M., Cruciani M., Mengoli C., et al. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy. 2007; 60(2):237-246.
54. Frydman G.H., Davis N., Beck P. L., Fox J. G. Helicobacter pylori eradication in patients with immune thrombocytopenic purpura: a review and the role of biogeography. Helicobacter. 2015;20(4):239-251. doi: 10.1111/hel.12200
55. Suzuki T., Matsushima M., Masui A., et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura- a randomized controlled trial. The American Journal of Gastroenterology. 2005;100(6):1265-1270. doi: 10.1111/j.1572-0241.2005.41641.x
56. Tsutsumi Y., Kanamori H., Yamato H., et al. Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. Annals of Hematology. 2005; 84 (12): 807-811. doi: 10.1007/s00277-005-1071-z
57. Kim B. J., Kim H. S., Jang H. J., et al. Helicobacter pylori eradication in idiopathic thrombocytopenic purpura: a meta-analysis of randomized trials. Gastroenterol Res Pract. 2018; 2018: 6090878. doi: 10.1155/2018/6090878
58. British Society for Haematology. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003; 120: 574-596.
59. Provan D., Arnold D. M., Bussel J. B., et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019 Nov 26; 3(22): 3780-3817. doi: 10.1182/bloodadvances.2019000812
60. Melikyan A. L., Pystovaya E. I., Tsvetaeva N. V. National clinical guidelines for diagnosis and treatment of idiopathic thrombocytopenic purpura. Moscow. 2018. 67 p. (in Russ.)@@ Меликян А.Л, Пустовая Е. И., Цветаева Н. В. Национальные клинические рекомендации по диагностике и лечению идиопатической тромбоцитопенической пурпуры у взрослых. М.: 2018-67 с
61. Gupta V., Eden A. J., Mills M. J. Helicobacter pylori and autoimmune neutropenia. Clin Lab Haematol. 2002;24:183-185.
62. Papadaki H.A., Pontikoglou C., Eliopoulos D. G., et al. Helicobacter pylori infection is probably the cause of chronic idiopathic neutropenia (CIN)-associated splenomegaly. Am J Hematol. 2006;81:142-144.
63. Cicconi V., Carloni E., Franceschi F., et al. Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication. Am J Med. 2001;111:163-164.
64. Reinauer S., Megahed M., Goerz G., et al. Schönlein-Henoch purpura associated with gastric Helicobacter pylori infection. J Am Acad Dermatol. 1995;33:876-879.
65. Grivceva-Panovska V., Grivceva Stardelova K., Serafimoski V. Henoch-Schönlein purpura in an adult patient: extragastric, cutaneous manifestation of helicobacter pylori infection. Prilozi. 2008;29:291-301.
66. Hoshino C. Adult onset Schönlein-Henoch purpura associated with Helicobacter pylori infection.Intern Med. 2009;48:847-851.
67. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
68. Malik A.A., Ganti A. K., Potti A., et al. Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. Am J Gastroenterol. 2002; 97:1371-1374.
69. Kato K., Sugitani M., Nagata T., Nishinarita S., et al. A case of gastric plasmacytoma associated with Helicobacter pylori infection: improvement of abnormal endoscopic and EUS findings after H. pylori eradication. Gastrointest Endosc. 2001;53:352-355.
70. Rajkumar S.V., Kyle R. A., Plevak M. F., et al. Helicobacter pylori infection and monoclonal gammopathy of undetermined significance. Br J Haematol. 2002;119:706-708.
71. Lehtinen M., Ogmundsdottir H. M., Bloigu A., et al. Associations between three types of maternal bacterial infection and risk of leukemia in the offspring. Am J Epidemiol. 2005;162:662-667.
72. Diamantidis M.D., Ioannidou-Papagiannaki E., Kountouras J., et al. High prevalence of Helicobacter pylori infection in Greek patients with myelodysplastic syndromes. ActaHaematol. 2010;124:141-149.
73. Dolatkhah R., Khoshbaten M., Asvadi Kermani I., et al. Upper gastrointestinal bleedings in patients with hereditary coagulation disorders in Northwest of Iran: prevalence of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2011;23:1172-1177.
74. Braden B., Wenke A., Karich H. J., et al. Risk of gastrointestinal bleeding associated with Helicobacter pylori infection in patients with hemophilia or von Willebrand’s syndrome. Helicobacter. 1998;3:184-187.
75. Tincani E., Bertoni G., Silingardi M., et al. Helicobacter pylori, a frequent and potentially dangerous guest in the gastroduodenal mucosa of anticoagulated patients. Am J Med. 2000;108:165-167.
76. Song H.J., Kwon J. W., Kim N., Park Y. S. Cost effectiveness associated with Helicobacter pylori screening and eradication in patients taking nonsteroidal antiinflammatory drugs and/or aspirin. Gut Liver. 2013;7:182-189.
Рецензия
Для цитирования:
Богданов А.Н., Волошин С.В., Кулибаба Т.Г. Инфекция Helicobacter pylori и гематологические заболевания. Экспериментальная и клиническая гастроэнтерология. 2022;(2):103-110. https://doi.org/10.31146/1682-8658-ecg-198-2-103-110
For citation:
Bogdanov A.N., Voloshin S.V., Kulibaba T.G. Helicobacter pylori infection and hematological diseases. Experimental and Clinical Gastroenterology. 2022;(2):103-110. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-198-2-103-110
Просмотров:
290
Послать статью по эл. почте 